Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation

NCT03718130 is registered in ClinicalTrials.gov with U.S. Army Medical Research and Development Command as lead sponsor.

NCT NCT03718130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03718130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation
Lead sponsor
U.S. Army Medical Research and Development Command
Phase
Phase 1
Overall status
Completed
Start date
July 10, 2019
Completion date
October 7, 2022
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hantaan virus disease, puumala virus